PBAC's latest decision on Amivantamab: Recommended with restriction (2024). Considered for First-line treatment of adults with locally advanced or metastatic NSCLC with activating EGFR exon 20 insertion mutations, in combination with platinum-based chemotherapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Treatment-naive adults with locally advanced or metastatic NSCLC with evidence of EGFR exon 20 insertion mutation, WHO performance status 2 or less.
Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
PFS
Key trials
PAPILLON
Comparator
platinum-based chemotherapy (carboplatin and pemetrexed)
Economic model
CUA
ICER note
ICER not stated in the public text; economic model details and values are not disclosed in the PSD.
Risk sharing
Risk-sharing arrangement in place — Special Pricing Arrangement (SPA) requested; sponsor proposes patient access program for approximately 20 patients with grandfathering provision.